Korea FDA Evaluating H1N1 Vaccine Applications from GSK and Three Korean Pharmas
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea FDA said it is evaluating three applications for the A/H1N1 flu vaccine submitted by GlaxoSmithKline and Korean companies Green Cross, Boryung Pharmaceutical and Hanwha Pharma